Immune response in ADEPT

Advanced Drug Delivery Reviews

Volumn 22, Issue 3, 1996, Pages 369-376

  Sharma, S K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

ADEPT; antibody enzyme conjugate; cyclosporin; immunogenicity

Indexed keywords

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIBODY ENZYME CONJUGATES; CANCER THERAPY; CYCLOSPORIN; IMMUNOGENICITY; IMMUNOSUPPRESSION; MURINE MONOCLONAL ANTIBODIES;

ANTIBODIES; DISEASES; ENZYMES; GENETIC ENGINEERING; IMMUNOLOGY;

DRUG THERAPY;

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BACTERIAL ENZYME; CARBOXYPEPTIDASE G2; CYCLOSPORIN A; ENZYME; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PRODRUG; PROTEIN; RADIOISOTOPE;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIBODY PRODUCTION; CANCER THERAPY; CLINICAL TRIAL; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MALAISE; MOUSE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; VOMITING;

EID: 0030589528     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00440-1     Document Type: Review

References (55)

1. [1] Bagshawe, K.D. (1987) Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer 56, 531-532.
2. [2] Bagshawe, K.D., Springer, C.J., Searle, F., Antoniw, P., Sharma, S.K., Melton, R.G. and Sherwood, R.F. (1988) A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 58, 700-703.
3. [3] Senter, P.D., Saulnier, M.G., Schreiber, G.J., Hirschberg, D.L., Brown, J.P., Hellstrom, I. and Hellstrom, K.E. (1988) Anti-tumour effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA 85, 4842-4846.
4. [4] Sharma, S.K., Bagshawe, K.D., Springer, C.J., Burke, P.J., Rogers, G.T., Boden, J.A., Antoniw, P., Melton, R.G. and Sherwood, R.F. (1991) Antibody directed enzyme prodrug therapy (ADEPT) - A three-phase system. Dis. Markers 9, 225-231.
5. [5] Bagshawe, K.D., Sharma, S.K., Springer, C.J., Antoniw, P., Boden, J.A., Rogers, G.T., Burke, P.J., Melton, R.G. and Sherwood, R.F. (1991) Antibody directed enzyme prodrug therapy (ADEPT) - Clinical report. Dis. Markers 9, 233-238.
6. [6] Bagshawe, K.D., Sharma, S.K., Springer, C.J. and Antoniw, P. (1995) Antibody-directed enzyme prodrug therapy: a pilot-scale clinical trial. Tumour Targeting 1, 1-13.
7. [7] Schroff, R.W., Foon, K.A., Beatty, S.M., Oldham, R.K. and Morgan, A.C. (1985) Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 45, 879.
8. [8] Khazaeli, M.B., Conry, R.M. and Lobuglio, A.F. (1994) Human immune response to monoclonal antibodies. J. Immunother. 15(1), 42-52.
9. [9] Dillman, R.O., Shawler, D.L., McCallister, T.J. and Halpern, S.E. (1994) Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabelled murine monoclonal antibodies. Cancer Biother. 9(1), 17-28.
10. [10] Borel, J.F., Feurer, C., Magnee, C. and Stahelin, H. (1977) Effects of the new anti-lymphocyte peptide cyclosporin A in animals. Immunology 32, 1017.
11. [11] Lindsey, N.J., Harris, K.R., Norman, H.B., Smith, J.L., Lee, H.A. and Slapek, M. (1982) The effect of cyclosporin A on the primary and secondary immune response in the rabbit. Transplant. Proc. 12, 252.
12. [12] Ledermann, J.A., Begent, R.H.J. and Bagshawe, K.D. (1988) Cyclosporin A prevents the anti-immune antibody response to a monoclonal anti-tumour antibody in rabbits. Br. J. Cancer 58, 562.
13. [13] Ledermann, J.A., Begent, R.H.J., Bagshawe, K.D., Riggs, S.J., Dearle, F., Glaser, M.G., Green, A.J. and Dale, R.G. (1988) Repeated anti-tumour antibody therapy in man with suppression of the host response by cyclosporin A. Br. J. Cancer 58, 654-657.
14. [14] Sharma, S.K., Bagshawe, K.D., Melton, R.G. and Begent, R.H.J. (1996) Effect of cyclosporin A on immunogenicity of a bacterial enzyme carboxypeptidase G2 in ADEPT. Transplant. Proc., in press.
15. [15] Sharma, S.K., Bagshawe. K.D., Melton, R.G. and Sherwood, R.F. (1993) Human immune response to monoclonal antibody-enzyme conjugates in ADEPT. Pilot clinical trial. Cell Biophys. 21, 109-119.
16. [16] Bagshawe, K.D. and Sharma, S.K. (1996) ADEPT: Clinical study with cyclosporin A to allow multiple cycles of therapy. Transplant. Proc., in press.
17. [17] Carrasquillo, J.A., Krohn, K.A., Beaumier, P. et al. (1984) Diagnosis and therapy for solid tumours with radiolabelled antibodies and immune fragments. Cancer Treat. Rep. 68, 317.
18. [18] Juweid, M., Sharkey, R.M., Behr, T. et al. (1996) Radioimmunotherapy of medullary-thyroid cancer with iodine-131-labelled anti-CEA antibodies. J. Nucl. Med. 37(6), 905-911.
19. [19] Lobuglio, A.F., Wheeler, R.H., Trang, J., Haynes, A., Rogers, K., Harvey, E.B., Sun, L., Ghrayeb, J. and Khazaeli, M.B. (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA 86, 4220-4224.
20. [20] Morrison, S.L. and Shin, S.U. (1995) Genetically-engineered antibodies and their application to brain delivery. Adv. Drug Deliv. Rev. 15(1-3), 147-175.
21. [21] Goodman, G.E., Hellstrom, I., Yelton, D.E. et al. (1993) Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small cell lung, colon, and breast cancer. Cancer Immunol. Immunother. 36, 267-273.
22. [22] McCabe, R.P., Peters, L.C., Haspel, M.V., Pomato, N., Carrasquillo, J.A. and Hanna, M.G. Jr. (1988) Preclinical studies on the pharmacokinetic properties of human monoclonal antibodies to colorectal cancer and their use for detection of tumours. Cancer Res. 48, 4348-4353.
23. [23] Haisma, H.J., Pinedo, H.M., Kessel, M.A.P. et al. (1991) Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients. J. Natl. Cancer Inst. 83, 1813-1819.
24. [24] Ledermann, J.A., Begent, R.H.J., Massof, C., Kelly, A.M., Adam, T. and Bagshawe, K.D. (1991) A phase 1 study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int. J. Cancer 47, 659-664.
25. [25] Waldmann, H. and Cobbold, S. (1993) The use of monoclonal antibodies to achieve immunological tolerance. Immunol. Today 14(6), 247-251.
26. [26] Houba, P.H.J., Leenders, R.G.G., Boven, E., Scheeren, J.W., Pinedo, H.M. and Haisma, H.J. (1996) Characterisation of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochem. Pharmacol. 52(3), 455-463.
27. [27] Bosslet, K., Czech, J., Lorenz, P., Sedlacek, H.H., Schuermann, M. and Seeman, G. (1992) Molecular and functional characteristics of a fusion protein suited for tumour specific prodrug activation. Br. J. Cancer 65, 234-238.
28. [28] Bosslet, K., Czech, J. and Hoffman, D. (1994) Tumour selective prodrug activation by fusion protein mediated catalysis. Cancer Res. 54(8), 2151-2159.
29. [29] Stephens, S., Emtage, S., Vetterlein, O. et al. (1995) Comprehensive pharmacokinetics of a humanised antibody and analysis of residual antiidiotypic responses. Immunology 85(4), 668-674.
30. [30] Pulito, V.L., Roberts, VA., Adair, J.R. et al. (1996) Humanisation and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. J. Immunol. 156(8), 2840-2850.
31. [31] Pimm, M.V. (1994) Possible consequences of human-antibody responses on the biodistribution of fragments of human, humanised or chimeric monoclonal antibodies - A note of caution. Life Sci. 55(2) PL45-PL49.
32. [32] Chen, S.Y., Zani, C., Khouri, Y. and Marasco, W.A. (1995) Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther. 2(2), 116-123.
33. [33] Kino, T., Hatanaka, H., Miyata, S., Inamura, N. et al. (1987) FK506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK506 in vitro. J. Antibiot. (Tokyo) 40, 1256-1265.
34. [34] Kahan, B.D., Chang, J.Y. and Sehgal, S.N. (1991) Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 52, 185-191.
35. [35] Morris, R.E., Wang, J. and Blum, J.R. (1991) Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipient of heart allografts. Transplant. Proc. 23(suppl. 2), 19-25.
36. [36] Deierhoi, M.H., Kauffman, R.S., Hudson, S.L. et al. (1993) Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann. Surg. 217(5) 476-484.
37. [37] Morris, R.E. (1993) New small molecule immunosuppressants for transplantation: Review of essential concepts. J. Heart Lung Transplant. 12(6)II, S275-S286.
38. [38] Fujii, H., Takada, T., Nemoto, K. et al. (1987) Deoxyspergualin directly suppresses antibody formation in vivo and in vitro. J. Antibiot. 43, 213-219.
39. [39] Dhingra, K., Fritsche, H., Murray, J.L., Lobuglio, A.F., Khazaeli, M.B. et al. (1995) Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res. 55, 3060-3067.
40. [40] Wilkinson, I., Jackson, C.J.S., Lang, G.M., Holford-Strevens, V. and Sehon, A.H. (1987) Tolerogenic polyethylene glycol derivatives of xenogenic monoclonal immunoglobulins. Immunol. Lett. 15, 17-22.
41. [41] Maiti, P.K., Lang, G.M. and Sehon, A.H. (1988) Tolerogenic conjugates of xenogenic monoclonal antibodies with monomethoxypolyethylene glycol. I. Induction of longlasting tolerance to xenogenic monoclonal antibodies. Int. J. Cancer suppl.(3), 17-22.
42. [42] Abuchowski, A., McCoy, J.R., Palczuk, N.C., van Es, T. and Davis, F.F. (1977) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252, 3582-3586.
43. [43] Kamisaki, Y., Wada, H., Yagura, T., Matsushima, A. and Inada, Y. (1981) Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J. Pharmacol. Exp. Ther. 216, 410-414.
44. [44] Sekine, T., Kodera, Y., Saito, T., Hiroto, M., Matsushima, A., Nishimura, H. and Inada, Y. (1995) t-Asparaginase modified by Poly(ethylene Glycol) derivative with a comb-shaped form-Antitumor-activity and induction of immune tolerance. Biomed. Res. 16(2), 121-123.
45. [45] Savoca, K.V., Davis, F.F. and Palezuk, N.C. (1984) Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase. Int. Arch. Allergy Appl. Immunol. 75, 58-67.
46. [46] Chaffee, S., Mary, A., Stiehm, E.R., Girault, D., Fischer, A. and Hershfield, M.S. (1992) IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J. Clin. Invest. 89, 1643-1651.
47. [47] Marshall, D., Pedley, R.B., Boden, J.A., Boden, R., Melton, R.G. and Begent, R.H.J. (1996) Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Br. J. Cancer 73, 565-572.
48. [48] Eno-Amooquaye, E.A., Searle, F., Boden, J.A., Sharma, S.K. and Burke, P.J. (1996) Altered biodistribution of an antibody-enzyme conjugate modified with polyethylene glycol. Br. J. Cancer 73, 1323-1327.
49. [49] Koprowski, H., Herlyn, D., Lubeck, M., DeFreitas, E. and Sears, H.F. (1984) Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc. Natl. Acad. Sci. USA 81, 216-219.
50. [50] Losman, M.J., Hansen, H.J., Sharkey, R.M., Goldenberg, D.M. and Monestier, M. (1991) Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumour antigen. Proc. Natl. Acad. Sci. USA 88, 3421-3425.
51. [51] Mittleman, A., Chen, Z.J., Yang, H. et al. (1992) Human high molecular weight melanoma associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. USA 89, 466-470.
52. [52] Baum, R.P., Niesen, A., Hertel, A. et al. (1994) Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 73, 1121-1125.
53. [53] Kosmas, C., Epenetos, A.A. and Courtenayluck, N.S. (1994) Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer 73, 3000-3010.
54. [54] Wentworth, P., Datta, A., Blakey, D., Boyle, T., Partridge, L.J. and Blackburn, G.M. (1996) Toward antibody-directed abzyme prodrug therapy, ADAPT-carbamate prodrug activation by a catalytic antibody and its in-vitro application to human tumor-cell killing. Proc. Natl. Acad. Sci. USA 93(2), 799-803.
55. [55] Duchosal, M.A., Rothermel, A.L., McConahey, P.J., Dixon, F.J. and Altieri, D.C. (1996) In-vivo immunosuppression by targeting a novel protease receptor. Nature 380, 352-356.